Online Comedians Are Making a Mint Mocking Wall Street
Johnny Hilbrant Partridge never worked an hour on Wall Street, but you’d never guess that by looking at him. Nearly every day, Partridge takes to YouTube to channel his inner finance bro as P.E. Guy, a puffer-vested private equity putz who brags about his million-dollar deals, Aspen manse and private plane.
Partridge, who once taught fitness classes in Boston,
» Read more about: Online Comedians Are Making a Mint Mocking Wall Street »
Read MoreWall Street Lowers the Bar: Why Ford’s Q3 Earnings on Oct. 28 Could Trigger a Surprise October Breakout
Ford reports Q3 earnings on October 28 with the stock already beaten down and analyst expectations trimmed, setting up a scenario where a modest beat could flip sentiment fast or confirm that something deeper is wrong with the recovery story.
Ford (NYSE:F | F Price Prediction) reports third-quarter results on October 28,
Wall Street Is Tying Bonuses to AI Skills. His $220,000 Paycheck Still Hits Social Security’s $184,500 Ceiling
Wall Street is rewarding AI skills with bigger paychecks, but a federal ceiling most high earners never think about quietly decides how much of that raise actually counts toward retirement.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Read MoreSocial Security recipients may see 2 payments this week. Here's why
Some Social Security recipients may see two payments hit their accounts this week.
The final round of October Social Security payments and the November Supplemental Security Income payment are both scheduled to go out this week.
Here’s what to know about upcoming Social Security and Supplemental Security Income payment dates.
» Read more about: Social Security recipients may see 2 payments this week. Here's why »
Read MoreThe Burst
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
Will This ETF 2x Before Year End?
In recent months, some of the most sophisticated investors on Wall Street have made a bold move by pouring hundreds of millions into BlackRock’s iShares Bitcoin Trust (IBIT).
This isn’t just a passing trade but a conviction bet that Bitcoin’s best days may still be ahead and while still trading under $100,000 per coin,
» Read more about: Will This ETF 2x Before Year End? »
Read MoreThe Spotlight
Why This Beverage Giant Can’t Be Toppled
A famous book on business was titled Barbarians at the Gate, documenting the leveraged buyout of RJR Nabisco. If nothing else, it highlights how just the sniff of an opportunity to make money can drive money seekers to make wild decisions.
Some giant businesses have been on the receiving end of similar threats to their solvency as invaders attempt to take their share.
» Read more about: Why This Beverage Giant Can’t Be Toppled »